je.st
news
Tag: abbvie
BPCIA: Amgen Begins the Patent Dance With AbbVie
2015-12-08 00:56:18| Biotech - Topix.net
On November 25, 2015, Amgen Inc. announced it submitted its first biologics license application to the FDA under the Section 351 biosimilar approval pathway provided in the Biologics Price Competition and Innovation Act . Amgen's BLA seeks approval for its biosimilar of AbbVie's top-selling arthritis drug Humira .
Tags: dance
begins
patent
amgen
FDA warns of deadly liver damage with AbbVie hepatitis drugs
2015-10-25 14:37:13| Biotech - Topix.net
Federal health officials are warning doctors and patients that two hepatitis C drugs from AbbVie can cause life-threatening liver injury in patients with advanced forms of the disease. The Food and Drug Administration said Thursday it will require AbbVie to add new warnings to Viekira Pak and Technivie after reported deaths and liver transplants in patients who already had liver damage caused by hepatitis C. The warning could reshape the growing field of high-priced drugs to treat the virus, which also includes Gilead Sciences' blockbuster medications Sovaldi and Harvoni.
Tags: damage
drugs
liver
deadly
FDA adds liver warning to AbbVie hepatitis C drugs
2015-10-23 01:36:32| Biotech - Topix.net
Federal health officials are warning doctors and patients that two hepatitis C drugs from AbbVie can cause life-threatening liver injury in patients with advanced forms of the disease. The Food and Drug Administration said Thursday it will require AbbVie to add new warnings to Viekira Pak and Technivie about their risks for patients who already have advanced liver damage caused by hepatitis C. The warning could reshape the growing field of high-priced drugs to treat the virus, which also includes Gilead Sciences' blockbuster medications Sovaldi and Harvoni.
Tags: warning
drugs
adds
liver
AbbVie, Biogen, Gilead: Smart Money Got Burned Betting on Biotech in Q3
2015-10-20 17:42:28| Biotech - Topix.net
When it rains, it pours, and for big pharma, it certainly poured in the third quarter. With the third quarter over, let's take a closer look at the fundamentals of hedge fund hotels Pfizer Inc. , Gilead Sciences, Inc. , AbbVie Inc , Amgen, Inc. , and Biogen Inc and see how they did in the third quarter .
Tags: money
smart
biotech
burned
Allergan may turn sights to Amgen or AbbVie with Teva cash
2015-07-28 18:30:04| Biotech - Topix.net
Allergan Plc says it's “reloaded and ready to move” on further acquisitions after agreeing to sell its generic-drug business for $40.5 billion. The deal with Teva Pharmaceutical Industries Ltd. “gives us a tremendous amount of flexibility to think about transformational M&A as well as continue our pattern of tuck-in acquisitions,” Allergan Chief Executive Officer Brent Saunders said on a conference call today.
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] next »